Considerations for Developing Applied Health Policy Models: The Example of HIV Treatment Expansion in Resource-Limited Settings

  • April D. Kimmel
  • Bruce R. Schackman
Part of the International Series in Operations Research & Management Science book series (ISOR, volume 190)


This chapter describes steps for developing health policy models. The discussion begins with considerations for identifying a research question and developing a model conceptual framework. It next provides guidance on how to build and implement the model, as well as how to populate or parameterize a model. We end by examining the techniques for verifying model performance. Special emphasis is placed on developing applied health policy models, particularly those used to inform policy decisions in resource-limited settings.


Cycle Length Model Input Policy Model Model Input Parameter Simple Model Structure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS et al. (2001) Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4:348–361CrossRefGoogle Scholar
  2. 2.
    Earp JA, Ennett ST (1991) Conceptual models for health education research and practice. Health Educ Res 6:163–171CrossRefGoogle Scholar
  3. 3.
    Paradies Y, Stevens M (2005) Conceptual diagrams in public health research. J Epidemiol Community Health 59:1012–1013CrossRefGoogle Scholar
  4. 4.
    (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299Google Scholar
  5. 5.
    Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B et al. (2007) Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21:685–692CrossRefGoogle Scholar
  6. 6.
    Mills EJ, Bakanda C, Birungi J, Chan K, Ford N et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155:209–216Google Scholar
  7. 7.
    World Health Organization, UNAIDS, UNICEF (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2010. World Health Organization, Geneva.
  8. 8.
    Clinton HR (2011) Remarks on “creating an AIDS-free generation”. Bethesda.
  9. 9.
    Bonnel R, de Beyer J, Bennett D (2009) The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact. The World Bank and UNAIDS.
  10. 10.
    Kates J, Wexler A, Lief E, Avila C, Gobet B (2011) Financing the response to AIDS in low- and middle-income countries: international assistance from the G8, European Commission and other donor governments in 2010.–07.pdf
  11. 11.
    Moszynski P (2011) Global fund suspends new projects until 2014 because of lack of funding. BMJ 343:d7755CrossRefGoogle Scholar
  12. 12.
    Rosen S, Fox MP, Gill CJ (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 4:e298CrossRefGoogle Scholar
  13. 13.
    World Health Organization (2011) Global health sector strategy on HIV/AIDS 2011–2015. World Health Organization.
  14. 14.
    World Health Organization (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision.
  15. 15.
    World Health Organization (2006) Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach. 2006 revision. World Health Organization,Geneva.
  16. 16.
    Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493–505CrossRefGoogle Scholar
  17. 17.
    Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375:2092–2098CrossRefGoogle Scholar
  18. 18.
    Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E et al. (2011) The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa. J Acquir Immune Defic Syndr 56:26–35CrossRefGoogle Scholar
  19. 19.
    Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E et al. (2010) Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 54:258–268CrossRefGoogle Scholar
  20. 20.
    Bishai D, Colchero A, Durack DT (2007) The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 21:1333–1340CrossRefGoogle Scholar
  21. 21.
    Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A (2011) Cost-effectiveness of antiretroviral regimens in the World Health Organization’s treatment guidelines: a South African analysis. AIDS 25:211–220CrossRefGoogle Scholar
  22. 22.
    Braithwaite RS, Nucifora KA, Yiannoutsos CT, Musick B, Kimaiyo S et al. (2011) Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc 14:38CrossRefGoogle Scholar
  23. 23.
    Kuntz KM, Weinstein MC (2001) Modelling in economic evaluation. In: Drummond M, McGuire A (eds) Economic evaluation in health care: merging theory with practice. Oxford University Press, New YorkGoogle Scholar
  24. 24.
    Dewilde S, Anderson R (2004) The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Med Decis Making 24:486–492CrossRefGoogle Scholar
  25. 25.
    Beck JR, Pauker SG (1983) The Markov process in medical prognosis. Med Decis Making 3:419–458CrossRefGoogle Scholar
  26. 26.
    Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338CrossRefGoogle Scholar
  27. 27.
    Benbassat J, Baumal R (2007) The time horizons of formal decision analyses. QJM 100:383–388CrossRefGoogle Scholar
  28. 28.
    Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS (1997) Primer on medical decision analysis: part 5—working with Markov processes. Med Decis Making 17:152–159CrossRefGoogle Scholar
  29. 29.
    Price MJ, Briggs AH (2002) Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 20:183–194CrossRefGoogle Scholar
  30. 30.
    Stahl JE (2008) Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 26:131–148CrossRefGoogle Scholar
  31. 31.
    Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M et al. (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices—modeling studies. Value Health 6:9–17CrossRefGoogle Scholar
  32. 32.
    Goldie SJ, Corso PS (2003) Decision analysis. In: Haddix AC, Teutsch SM, Corso PS (eds) Prevention effectiveness, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  33. 33.
    Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK et al. (In press) State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force working group—part 5. Value HealthGoogle Scholar
  34. 34.
    Kimmel AD, Fitzgerald DW, Charles M, Edwards AM, Marcelin A et al. (2012) Internal validation and calibration of a model to forecast HIV treatment demand and capacity in Haiti. Med Decis Making 32:E123Google Scholar
  35. 35.
    Alistar SS, Brandeau ML (2012) Decision making for HIV prevention and treatment scale up: bridging the gap between theory and practice. Med Decis Making 32:105–117CrossRefGoogle Scholar
  36. 36.
    Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24:1043–1053CrossRefGoogle Scholar
  37. 37.
    Kuntz KM, Weinstein MC (1995) Life expectancy biases in clinical decision modeling. Med Decis Making 15:158–169CrossRefGoogle Scholar
  38. 38.
    UNAIDS (2011) AIDSinfo database.
  39. 39.
    Greasley A (1998) An example of a discrete-event simulation on a spreadsheet. Simulation 70:148–166CrossRefGoogle Scholar
  40. 40.
    Briggs AH, Fenwick E, Karnon J, Paltiel AD, Schulpher M et al. (2012) DRAFT model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force working group-6.
  41. 41.
    Porta MS (ed) (2008) A dictionary of epidemiology. Oxford University Press, OxfordGoogle Scholar
  42. 42.
    Lindgren BW (1993) Statistical theory. Chapman & Hall, New York, NYGoogle Scholar
  43. 43.
    Briggs AH, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation.Oxford University Press, New YorkGoogle Scholar
  44. 44.
    Concato J, Peduzzi P, Huang GD, O’Leary TJ, Kupersmith J (2010) Comparative effectiveness research: what kind of studies do we need? J Investig Med 58:764–769Google Scholar
  45. 45.
    Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New YorkGoogle Scholar
  46. 46.
    Taylor DC, Pawar V, Kruzikas D, Gilmore KE, Pandya A et al. (2010) Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics 28:995–1000CrossRefGoogle Scholar
  47. 47.
    Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM et al. (2012) DRAFT—model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force working group—part 4.
  48. 48.
    Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS (2009) Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 27:533–545CrossRefGoogle Scholar
  49. 49.
    McCabe C, Dixon S (2000) Testing the validity of cost-effectiveness models. Pharmacoeconomics 17:501–513CrossRefGoogle Scholar
  50. 50.
    Karnon J, Vanni T (2011) Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria. Pharmacoeconomics 29:51–62CrossRefGoogle Scholar
  51. 51.
    Vanni T, Karnon J, Madan J, White RG, Edmunds WJ et al. (2011) Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 29:35–49CrossRefGoogle Scholar
  52. 52.
    Hammerschmidt T, Goertz A, Wagenpfeil S, Neiss A, Wutzler P et al. (2003) Validation of health economic models: the example of EVITA. Value Health 6:551–559CrossRefGoogle Scholar
  53. 53.
    Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL et al. (2007) Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 166:137–150CrossRefGoogle Scholar
  54. 54.
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ (2002) Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 156:761–773CrossRefGoogle Scholar
  55. 55.
    Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY et al. (2008) Development of an empirically calibrated model of gastric cancer in two high-risk countries. Cancer Epidemiol Biomarkers Prev 17:1179–1187CrossRefGoogle Scholar
  56. 56.
    Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B et al. (2010) Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One 5(9):e12647CrossRefGoogle Scholar
  57. 57.
    Vanni T, Legood R, White RG (2010) Calibration of disease simulation model using an engineering approach. Value Health 13:157CrossRefGoogle Scholar
  58. 58.
    Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V et al. (2006) The wisconsin breast cancer epidemiology simulation model. J Natl Cancer Inst Monogr (36):37–47CrossRefGoogle Scholar
  59. 59.

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of Healthcare Policy and ResearchVirginia Commonwealth University School of MedicineRichmondUSA
  2. 2.Department of Public HealthWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations